Healthcare provider profile · identity verified

Andrew R Izzo, DO

Family Practice · GRAND RAPIDS, MI · NPI 1639699481

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	317	107
Rosuvastatin Calcium	Rosuvastatin Calcium	222	71
Lisinopril	Lisinopril	174	54
Omeprazole	Omeprazole	159	53
Losartan Potassium	Losartan Potassium	155	50
Amlodipine Besylate	Amlodipine Besylate	147	45
Levothyroxine Sodium	Levothyroxine Sodium	126	37
Hydrochlorothiazide	Hydrochlorothiazide	124	40
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	115	115
Tamsulosin Hcl	Tamsulosin Hcl	104	41
Metoprolol Succinate	Metoprolol Succinate	97	33
Metformin Hcl	Metformin Hcl	95	32
Telmisartan	Telmisartan	88	26
Trazodone Hcl	Trazodone Hcl	76	30
Escitalopram Oxalate	Escitalopram Oxalate	73	27
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	72	72
Allopurinol	Allopurinol	70	23
Simvastatin	Simvastatin	68	23
Gabapentin	Gabapentin	64	25
Metformin Hcl Er	Metformin Hcl	62	18
Meloxicam	Meloxicam	60	29
Eliquis	Apixaban	59	16
Mounjaro	Tirzepatide	50	11
Pantoprazole Sodium	Pantoprazole Sodium	50	16
Tramadol Hcl	Tramadol Hcl	46	14
Alendronate Sodium	Alendronate Sodium	41	13
Finasteride	Finasteride	41	16
Carvedilol	Carvedilol	40	13
Shingrix	Varicella-Zoster Ge/As01b/Pf	38	30
Triamcinolone Acetonide	Triamcinolone Acetonide	38	26
Duloxetine Hcl	Duloxetine Hcl	37	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	14
Sertraline Hcl	Sertraline Hcl	36	12
Glipizide Er	Glipizide	35	11
Albuterol Sulfate Hfa	Albuterol Sulfate	34	21
Citalopram Hbr	Citalopram Hydrobromide	33	12
Trulicity	Dulaglutide	33	suppressed
Famotidine	Famotidine	32	11
Jardiance	Empagliflozin	32	11
Furosemide	Furosemide	30	14
Lovastatin	Lovastatin	30	11
Mirtazapine	Mirtazapine	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Warfarin Sodium	Warfarin Sodium	29	suppressed
Ezetimibe	Ezetimibe	28	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	28	14
Pravastatin Sodium	Pravastatin Sodium	28	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	27	suppressed
Farxiga	Dapagliflozin Propanediol	25	suppressed
Irbesartan	Irbesartan	25	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Ramipril	Ramipril	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Cephalexin	Cephalexin	22	20
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Celecoxib	Celecoxib	20	suppressed
Prednisone	Prednisone	20	17
Bupropion Xl	Bupropion Hcl	19	suppressed
Alprazolam	Alprazolam	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Lansoprazole	Lansoprazole	18	suppressed
Ozempic	Semaglutide	18	suppressed
Potassium Chloride	Potassium Chloride	18	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Amoxicillin	Amoxicillin	16	13
Indapamide	Indapamide	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Benzonatate	Benzonatate	14	14
Cefdinir	Cefdinir	14	12
Chlorthalidone	Chlorthalidone	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Clotrimazole	Clotrimazole	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error